



Regd. Office : 1105,1106 Hubtown Solaris, N. S. Phadke Marg, Opp. Teligali, Andheri -East, Mumbai - 400 069.

Tel. : +91-22-2682 1055 / 1059 / 2683 7116 • Email : medicoremedies@yahoo.com, info@medicoremedies.com • Website : www.medicoremediesindia.com

Date: 14th November 2018

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Script Code : 540937

Dear Sir,

Re.: Outcome of the Board Meeting held today

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. we hereby inform you that at the Meeting of Board of Directors of our Company held on today i.e. 14th November, 2018 has, inter alia considered and approved the following:

1. Un-audited Financial Results of the Company for the half year ended on 30th September, 2018.

The Board has approved Unaudited Financial Results for the half year ended 30th September, 2018 along with the Limited Review Report thereon.

We wish to inform you that the Board Meeting commenced today at 11.00 A.M and concluded at 12.30 P.M

Kindly take the same on record and oblige.

Yours faithfully,

For MEDICO REMEDIES LIMITED

Harshit Mehta

**HARSHIT MEHTA
MANAGING DIRECTOR
DIN: 05144280**

MEDICO REMEDIES LIMITED
CIN: U24230MH1994PLC077187

Statement of unaudited Financial Results for the half year ended 30th September 2018. (Rs. In Lacs)

Sn	Particulars	6 months ended 30.09.2018	6 months ended 30.09.2017	6 months ended 31.03.2018	Year ended 31.03.2018
		Unaudited	Audited	Audited	Audited
I	Revenue From Operations	4,146.98	2,927.42	3,175.04	6,102.46
II	Other Income	127.19	48.59	42.70	91.30
III	Total Revenue	4,274.17	2,976.01	3,217.74	6,193.75
IV	<u>Expenses</u>				
(a)	Cost of Material Consumed	3,466.86	2,144.40	2,387.03	4,531.43
(b)	Purchase of Stock-in-Trade	91.16	24.41	40.03	64.44
(c)	Changes in Inventories of Finished Goods, Work in Progress and Stock in Trade	-197.08	-79.13	-167.24	-246.37
(d)	Employee Benefits Expenses	171.94	185.18	204.27	389.45
(e)	Finance Cost	52.17	95.38	56.30	151.68
(f)	Depreciation and Amortisation Expenses	71.38	48.72	51.75	100.46
(g)	Other Expenses	549.92	494.96	520.42	1,015.38
	Total Expenses	4,206.34	2,913.91	3,092.57	6,006.48
V	Profit before exceptional and extraordinary items and tax	67.83	62.11	125.17	187.28
VI	Exceptional items	-	-	-	-
VII	Profit before extraordinary items and tax	67.83	62.11	125.17	187.28
VIII	Extraordinary items	-	-	-	-
IX	Profit before tax	67.83	62.11	125.17	187.28
X	<u>Tax expense</u>				
(a)	Current Tax	18.32	18.00	37.00	55.00
(b)	Deferred Tax	4.11	4.09	6.17	10.26
(c)	Excess Provision	-	-	-	-
XI	Profit for the period from continuing operations	45.40	40.02	82.00	122.02
XII	Profit/(loss) from discontinuing operations	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-
XIV	Profit/(loss) from Discontinuing operations (after tax)	-	-	-	-
XV	Profit for the period	45.40	40.02	82.00	122.02
XVI	Earnings Per Equity Share				
(a)	Basic	1.09	1.25	4.74	3.65
(b)	Diluted	1.09	1.25	4.74	3.65
	See accompanying note to Financial Results				

FOR MEDICO REMEDIES LTD.

H. M. N. S.

Director

MEDICO REMEDIES LIMITED
CIN: U24230MH1994PLC077187
Balance Sheet As At 30Th September 2018 (Rs. In Lacs)

Sr.	Particulars	As at 30.09.2018	As at 30.09.2017	As at 31.03.2018
		Unaudited	Audited	Audited
I	EQUITY AND LIABILITIES			
1	Shareholders' Funds			
(a)	Share Capital	414.92	320.00	414.92
(b)	Reserves and Surplus	2,297.05	1,357.20	2,251.64
(c)	Money received against share warrants	-	-	-
	Sub-total - Shareholders' funds	2,711.97	1,677.20	2,666.56
2	Share application money pending allotment			
	Sub-total - Share application money pending allotment	-	-	-
3	Non-Current Liabilities			
(a)	Long-Term Borrowings	187.28	1,014.70	218.99
(b)	Deferred Tax Liabilities (Net)	15.93	5.66	11.83
(c)	Other Long Term Liabilities	15.00	24.71	15.00
(d)	Long Term Provisions	13.93	10.69	8.93
	Sub-total - Non-current liabilities	232.14	1,055.76	254.75
4	Current Liabilities			
(a)	Short-Term Borrowings	967.36	827.27	968.79
(b)	Trade Payables	-	-	-
	i. Total outstanding dues of micro enterprises and small enterprises	-	-	-
	ii. Total outstanding dues of creditors other than micro enterprises and small enterprises	2,185.73	1,193.92	1,768.37
(c)	Other Current Liabilities	186.17	105.01	280.05
(d)	Short Term Provisions	-	-	-
	Sub-total - Current liabilities	3,339.26	2,126.20	3,017.21
	TOTAL - EQUITY AND LIABILITIES	6,283.37	4,859.16	5,938.52
B	ASSETS			
1	Non Current Assets			
(a)	Fixed Assets			
	i. Tangible Assets	1,097.67	664.96	663.07
	ii. Intangible Assets	-	-	-
	iii. Capital Work-in-Progress	-	332.53	436.93
	iv. Intangible Assets under development	-	-	-
(b)	Non-Current Investments	23.69	58.18	23.78
(c)	Deferred tax assets (net)	-	-	-
(d)	Long-Term Loans and Advances	351.88	38.78	245.70
(e)	Other non-current assets	-	-	-
	Sub-total - Non-current assets	1,473.24	1,094.45	1,369.47
2)	Current Assets			
(a)	Current Investments	-	-	-
(b)	Inventories	1,494.59	1,168.50	1,491.05
(c)	Trade Receivables	1,940.22	1,399.45	1,700.86
(d)	Cash & Cash Equivalents	15.41	41.42	81.40
(e)	Bank Balancr other than cash and cash equivalents	-	-	-
(f)	Short-Term Loans and Advances	1,183.20	1,114.40	1,234.02
(g)	Other Current Assets	176.72	40.94	61.71
	Sub-total - Current assets	4,810.13	3,764.71	4,569.05
	TOTAL - ASSETS	6,283.37	4,859.16	5,938.52

FOR MEDICO REMEDIES LTD.

Handwritten signature

Director

Medico Remedies Limited
CIN: U24230MH1994PLC077187

Notes to the Statement of unaudited Financial Results for the half year ended 30th September 2018.

1. The above audited standalone financial results of the company were reviewed and recommended by the audit committee on 14th November, 2018 and subsequently approved by the Board of Directors at its meeting held on the 14th November, 2018. The review report has been filed with stock exchange and is available on the Company's website.
2. The standalone financial results for the 6 months ended 30th September 2018 have been subjected to Limited Review by statutory auditors of the company.
3. The figures for the half year ended 31st March, 2018 are balancing figures between audited figures of full financial year and audited year to date figures upto the half year ended 30th September 2017.
4. There are no separate reportable segments in terms of Accounting Standards-17.
5. There are no Investor complaints pending as on 30th September 2018.
6. Previous periods' figures have been regrouped / reclassified where required to make them compatible with the figures of current periods.

FOR MEDICO REMEDIES LTD.

H. Menla

Director

Limited Review Report on Six Monthly and Year to Date unaudited Standalone Financial Results of Medico Remedies Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of
Medico Remedies Limited

We have reviewed the accompanying statement of unaudited standalone financial results ('the Statement') of Medico Remedies Limited ('the Company') for the six months ended 30th September 2018, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 14th November 2018. Our responsibility is to issue a report on the Statement based on our review.

We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards notified under Section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules: 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai

**For V J SHAH & Co.
Chartered Accountants
Firm's Registration No: 109823W**



Chintan V. Shah
**(Chintan V. Shah)
Partner**

Date: 14.11.2018

Membership No.164370